 On Thursday, Osmotica Pharmaceuticals NASDAQ: OSMT -- a small-cap biopharmaceutical company -- announced that the U.S. Food and Drug Administration FDA had approved Upneeq, a therapy the company developed for the treatment of acquired blepharoptosis. This approval seems to have investors excited, and it may have been the catalyst for Osmoticas shares soaring on Friday. Acquired blepharoptosis is a condition that affects a patients upper eyelid. 